Defendant Name: DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation)

Defendant Type: Public Company
SIC Code: 2834
CUSIP: 00547W30

Initial Case Details

Legal Case Name In the Matter of DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation) and Robert O. Hopkins
First Document Date 14-Jan-2025
Initial Filing Format Administrative Action
File Number 3-22416
Allegation Type Issuer Reporting and Disclosure

Violations Alleged

Exchange Act
• Sec 10(b) + Rule 10b-5
• Rule 12b-20
• Sec 13(a)
• Rule 13a-1
• Rule 13a-13
• Sec 13(b)(2)(A)
• Sec 13(b)(2)(B)
Securities Act
• Sec 17(a)(1)
• Sec 17(a)(2)
• Sec 17(a)(3)
Additionally, Robert O. Hopkins is alleged to have caused DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation)'s violation of Rule 12b-20 of the Exchange Act.
Robert O. Hopkins is alleged to have caused DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation)'s violation of Sec 13(a) of the Exchange Act.
Robert O. Hopkins is alleged to have caused DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation)'s violation of Rule 13a-1 of the Exchange Act.
Robert O. Hopkins is alleged to have caused DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation)'s violation of Rule 13a-13 of the Exchange Act.
Robert O. Hopkins is alleged to have caused DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation)'s violation of Sec 13(b)(2)(A) of the Exchange Act.
Robert O. Hopkins is alleged to have caused DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation)'s violation of Sec 13(b)(2)(B) of the Exchange Act.
Robert O. Hopkins is alleged to have caused DMK Pharmaceuticals Corporation (f/k/a Adamis Pharmaceuticals Corporation)'s violation of Sec 17(a)(2) of the Securities Act.

Resolutions

First Resolution Date 14-Jan-2025
Headline Total Penalty and Disgorgement

See Related Documents

Related Documents:

33-11353 14-Jan-2025 Administrative Proceeding
Order Instituting Administrative and Cease-and-Desist Proceedings, Pursuant to Section 8A of the Securities Act of 1933, Sections 4C and 21C of the Securities Exchange Act of 1934, and Rule 102(e) of the Commission's Rules of Practice, Making Findings, and Imposing Remedial Sanctions and a Cease-and-Desist Order
On January 14, 2025, the SEC instituted settled administrative and cease-and-desist proceedings against DMK Pharmaceuticals Corporation, formerly known as Adamis Pharmaceuticals Corporation, and Robert O. Hopkins, stating: "These proceedings arise out of an accounting and disclosure fraud case concerning DMK Pharmaceuticals Corporation f/k/a Adamis Pharmaceuticals Corporation (“DMK Pharmaceuticals” or “Adamis”) and Robert O. Hopkins, its former Chief Financial Officer."
33-11353-s 14-Jan-2025 Administrative Summary
SEC Sues Pharmaceutical Company for Accounting and Disclosure Fraud and Bars Its Former Chief Financial Officer
On January 14, 2025, the SEC "announced settled charges against DMK Pharmaceuticals Corporation f/k/a Adamis Pharmaceuticals("Adamis") and Robert O. Hopkins ("Hopkins"), its former Chief Financial Officer, for a fraudulent scheme to generate revenues using illegal prescriptions."

Other Defendants in Action:

Robert O. Hopkins